

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: [doi:10.31222/osf.io/9sm4x](https://doi.org/10.31222/osf.io/9sm4x)). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Page 4, Line 138,144	Section Materials and Methods, Paragraph 2-3
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	No cell lines in this study were used.	n/a
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	No cell lines in this study were used.	n/a
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	There were no animal experiments in this study.	n/a
Animal observed in or captured from the field: Provide species, sex and age where possible	There were no animal experiments in this study.	n/a
Model organisms: Provide Accession number in repository (where relevant) OR RRID	There were no animal experiments in this study.	n/a
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	There were no plants and microbes in this study.	n/a
Microbes: provide species and strain, unique accession number if available, and source	There were no plants and microbes in this study.	n/a
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Page 3, Line 130	Section Materials and Methods, Paragraph 1
Provide statement confirming informed consent obtained from study participants.	Page 3, Line 131	Section Materials and Methods, Paragraph 1
Report on age and sex for all study participants.	Page 4, Line 171	Section Results, Paragraph 1

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	Page 3, Line 115	Section Materials and Methods, Paragraph 1
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	There were no detailed step-by-step protocols in this study.	n/a
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, or if they were not carried out.		
Sample size determination	Page 3, Line 123	Section Materials and Methods, Paragraph 1
Randomisation	This study was a prospective observational clinical research study. There will be no randomization.	n/a
Blinding	This study was a prospective observational clinical research study. No blinding was utilized.	n/a
Inclusion/exclusion criteria	Page 3, Line 119	Section Materials and Methods, Paragraph 1
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Page 4, Line 140,148	Section Materials and Methods, Paragraph 2-3
Define whether data describe technical or biological replicates	Page 4, Line 140	Section Materials and Methods, Paragraph 2
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Page 3, Line 130	Section Materials and Methods, Paragraph 1
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	There were no animal experiments in this study.	n/a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Page 3, Line 130	Section Materials and Methods, Paragraph 1
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	The study was not subject to dual use research of concern.	n/a

Analysis

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	Page 3, Line 121	Section Materials and Methods, Paragraph 1
Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of tests.	Page 4, Line 160	Section Materials and Methods, Paragraph 5
Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	The datasets analysed during the current study are available in the Resman, www.medresman.org.cn .	n/a
If data are publicly available, provide accession number in repository or DOI or URL.	The data are not publicly available.	n/a
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	No publicly available data are reused in this study.	n/a
Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.	Page 4, Line 160	Section Materials and Methods, Paragraph 5
If code is publicly available, provide accession number in repository, or DOI or URL.	No code was used in this study.	n/a

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: <http://dx.doi.org/10.21037/tcr-20-2791>